CYP2C9 and ABCG2 polymorphisms as risk factors for developing adverse drug reactions in renal transplant patients taking fluvastatin: A case-control study

Pharmacogenomics

Volumn 14, Issue 12, 2013, Pages 1419-1431

  Miroševic Skvrce, Nikica ^a   Božina, Nada ^b   Zibar, Lada ^c   Barišic, Ivan ^b   Pejnovic, Lana ^b   Macolic Šarinic, Viola ^a  

^a Agency for Medicinal Products and Medical Devices   (Croatia)

^b KBC Zagreb   (Croatia)

^c UNIVERSITY HOSPITAL OSIJEK   (Croatia)

Author keywords

ABCG2; adverse drug reactions; CYP2C9; drug interactions; fluvastatin; hydroxymethylglutaryl CoA reductase inhibitors; pharmacogenetics

Indexed keywords

ALANINE; BREAST CANCER RESISTANCE PROTEIN; CYSTEINE; CYTOCHROME P450 2C9; CYTOCHROME P450 INHIBITOR; FLUINDOSTATIN;

ABCG2 GENE; ADULT; ADVERSE OUTCOME; AGE DISTRIBUTION; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; CYP2C9 GENE; DRUG BLOOD LEVEL; DRUG SAFETY; FEMALE; GENETIC ASSOCIATION; GENETIC CODE; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GRAFT RECIPIENT; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; KIDNEY TRANSPLANTATION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MUSCLE CRAMP; MYALGIA; MYOPATHY; RHABDOMYOLYSIS; RISK FACTOR; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ARYL HYDROCARBON HYDROXYLASES; ATP-BINDING CASSETTE TRANSPORTERS; CASE-CONTROL STUDIES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FATTY ACIDS, MONOUNSATURATED; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; INDOLES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASM PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 84883893601     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.135     Document Type: Article

References (64)

1. Lindholm A, Albrechtsen D, Frödin L, Tufveson G, Persson NH, Lundgren G. Ischemic heart disease - major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation 60(5), 451-457 (1995
2. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J. Am. Soc. Nephrol. 9(Suppl. 12), S16-S23 (1998
3. Holdaas H, Fellström B, Jardine AG et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: A multicentre, randomised, placebo controlled trial. Lancet 361(9374), 2024-2031 (2003
4. Holdaas H, Fellström B, Cole E et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: The ALERT extension study. Am. J. Transplant. 5(12), 2929-2936 (2005
5. Stroes E. Statins and LDL-cholesterol lowering: An overview. Curr. Med. Res. Opin. 21(Suppl. 6), S9-S16 (2005
6. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drug: Mechanisms and clinical relevance. Clin. Pharmacol. Ther. 80(6), 565-581 (2006
7. Hurst FP, Neff RT, Jindal RM et al. Incidence, predictors and associated outcomes of rhabdomyolysis after kidney transplantation. Nephrol. Dial. Transplant. 24(12), 3861-3866 (2009
8. Riella LV, Gabardi S, Chandraker A. Dyslipidemia and its therapeutic challenges in renal transplantation. Am. J. Transplant. 12(8), 1975-1982 (2012
9. Park JW, Siekmeier R, Lattke P, Merz M, Mix C, Schuler S. Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine. J. Cardiovasc. Pharmacol. Ther. 6(4), 351-361 (2001
10. Goldberg R, Roth D. Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine. Transplantation 62(11), 1559-1564 (1996
11. Barshes NR, Goodpastor SE, Goss JA. Sirolimus-atorvastatin drug interaction in the pancreatic islet transplant recipient. Transplantation 76(11), 1649-1650 (2003
12. Dopazo C, Bilbao I, Lázaro JL et al. Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin with rapamycin plus tacrolimus in liver transplant patient. Transplant. Proc. 41(3), 1021-1024 (2009
13. Basic-Jukic N, Kes P, Bubic-Filipi L, Vranjican Z. Rhabdomyolysis and acute kidney injury secondary to concomitant use of fluvastatin and rapamycin in a renal transplant recipient. Nephrol. Dial. Transplant. 25(6), 2036 (2010
14. Kotanko P, Kiristis W, Skrabal F. Rhabdomyolysis and acute renal graft impairment in a patient treated with simvastatin, tacrolimus and fusidic acid. Nephron 90(2), 234-235 (2002
15. Law M, Rudnicka AR. Statin safety: A systematic review. Am. J. Cardiol. 97(8A), 52C-60C (2006
16. Ballantyne CM, Blazing MA, Hunninghake DB et al Effect on high-density lipoprotein cholesterol of maximum dose simvastatin and atorvastatin in patients with hypercholesterolemia: Results of the Comparative HDL Efficacy and Safety Study (CHESS). Am. Heart J. 146(5), 862-869 (2003
17. Illingworth DR, Crouse JR 3rd, Hunninghake DB et al. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial. Curr. Med. Res. Opin. 17(1), 43-50 (2001
18. Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann. Pharmacother. 35(9), 1096-1107 (2001
19. Armitage J. The safety of statins in clinical practice. Lancet 370(9601), 1781-1790 (2007
20. Pasternak RC, Smith SC, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. American College of Cardiology; American Heart Association; National Heart, Lung and Blood Institute. J. Am. Coll. Cardiol. 40(3), 567-572 (2002
21. Chatzizisis YS, Koskinas KC, Misirli G, Vaklavas C, Hatzitolios A, Giannoglou GD. Risk factors and drug interactions predisposing to statin-induced myopathy: Implications for risk assessment, prevention and treatment. Drug Saf. 33(3), 171-187 (2010
22. Scripture CD, Pieper JA. Clinical pharmacokinetics of fluvastatin. Clin. Pharmacokinet. 40(4), 263-281 (2001
23. Niemi M. Transporter pharmacogenetics and statin toxicity. Clin. Pharmacol. Ther. 87(1), 130-133 (2010
24. Romaine SP, Bailey KM, Hall AS, Balmforth AJ. The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. Pharmacogenomics J. 10(1), 1-11 (2010
25. Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br. J. Pharmacol. 158(3), 693-705 (2009
26. Link E, Parish S, Armitage J et al. SLCO1B1 variants and statin-induced myopathy - A genomewide study. N. Engl. J. Med. 359(8), 789-799 (2008
27. Voora D, Shah SH, Spasojevic I et al. The SLCO1B1. *5 genetic variant is associated with statin-induced side effects. J. Am. Coll. Cardiol. 54(17), 1609-1616 (2009
28. Brunham LR, Lansberg PJ, Zhang L et al. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J. 12(3), 233-237 (2011
29. Puccetti L, Ciani F, Auteri A. Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study. Atherosclerosis 211(1), 28-29 (2010
30. Wilke RA, Ramsey LB, Johnson SG et al. CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin. Pharmacol. Ther. 92(1), 112-117 (2012
31. Keskitalo JE, Pasanen MK, Neuvonen PJ, Niemi M. Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. Pharmacogenomics 10(10), 1617-1624 (2009
32. Kirchheiner J, Kudlicz D, Meisel C et al. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. Clin. Pharmacol. Ther. 74(2), 186-194 (2003
33. Niemi M, Pasanen MK, Neuvonen PJ. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin. Pharmacol. Ther. 80(4), 356-366 (2006
34. Keskitalo JE, Kurkinen KJ, Neuvonen M, Backman JT, Neuvonen PJ, Niemi M. No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin. Br. J. Clin. Pharmacol. 68(2), 207-213 (2009
35. Robey RW, Ierano C, Zhan Z, Bates SE. The challenge of exploiting ABCG2 in the clinic. Curr. Pharm. Biotechnol. 12(4), 595-608 (2011
36. Rettie AE, Jones JP. Clinical and toxicological relevance of CYP2C9: Drug-drug interactions and pharmacogenetics. Annu. Rev. Pharmacol. Toxicol. 45, 477-494 (2005
37. Karch FE, Lasagna L. Adverse drug reactions - A critical review. JAMA 234(12), 1236-1241 (1975
38. Danan G, Benichou C. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: Application to drug-induced liver injuries. J. Clin. Epidemiol. 46(11), 1323-1330 (1993
39. Council for International Organizations of Medical Sciences. Current Challenges in Pharmacovigilance: Pragmatic Approaches. Report of CIOMS Working Group V. CIOMS, Geneva, Switzerland (2001
40. Aithal GP, Watkins PB, Andrade RJ et al. Case definition and phenotype standardization in drug-induced liver injury. Clin. Pharmacol. Ther. 89(6), 806-815 (2011
41. Wang B, Wang J, Huang SQ, Su HH, Zhou SF. Genetic polymorphism of the human cytochrome P450 2C9 gene and its clinical significance. Curr. Drug Metab. 10(7), 781-783 (2009
42. He SM. Clinical drugs undergoing polymorphic metabolism by human cytochrome P450 2C9 and the implication in drug development. Curr. Med. Chem. 18(5), 667-713 (2011
43. Holstein A, Hahn M, Patzer O, Seeringer A, Kovacs P, Stingl J. Impact of clinical factors and CYP2C9 variants for the risk of severe sulfonylurea-induced hypoglycemia. Eur. J. Clin. Pharmacol. 67(5), 471-476 (2011
44. Kamiyama E, Yoshigae Y, Kasuya A, Takei M, Kurihara A, Ikeda T. Inhibitory effects of angiotensin receptor blockers on CYP2C9 activity in human liver microsomes. Drug Metab. Pharmacokinet. 22(4), 267-275 (2007
45. Taavitsainen P, Kiukaanniemi K, Pelkonen O. In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists. Eur. J. Clin. Pharmacol. 56(2), 135-140 (2000
46. Wen X, Wang JS, Backman JT, Laitila J, Neuvonen PJ. Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively. Drug Metab. Dispos. 30(6), 631-635 (2002
47. Enokizono J, Kusuhara H, Sugiyama Y. Regional expression and activity of breast cancer resistance protein (Bcrp/Abcg2) in mouse intestine: Overlapping distribution with sulfotransferases. Drug Metab. Dispos. 35(6), 922-928 (2007
48. Takara K, Sakaeda T, Kakumoto M et al. Effects of a-adrenoceptor antagonist doxazosin on MDR1-mediated multidrug resistance and transcellular transport. Oncol. Res. 17(11-12), 527-533 (2009
49. Adkison KK, Vaidya SS, Lee DY et al. Oral sulfasalazine as a clinical BCRP probe substrate: Pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration. J. Pharm. Sci. 99(2), 1046-1062 (2010
50. Breedveld P, Zelcer N, Pluim D et al. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: Potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res. 64(16), 5804-5811 (2004
51. Suzuki K, Doki K, Homma M et al. Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br. J. Clin. Pharmacol. 67(1), 44-49 (2009
52. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16(3), 1215 (1988
53. Haque KA, Pfeiffer RM, Beerman MB et al. Performance of high-throughput DNA quantification methods. BMC Biotechnol. 28, 3-20 (2003
54. Guo SW, Thompson EA. A Monte Carlo method for combined segregation and linkage analysis. Am. J. Hum. Genet. 51(5), 1111-1126 (1992
55. Slatkin M, Excoffier L. Testing for linkage disequilibrium in genotypic data using the expectation-maximization algorithm. Heredity (Edinb.) 76(Pt 4), 377-383 (1996
56. Excoffier L, Lischer HE. Arlequin suite ver 3.5: A new series of programs to perform population genetics analyses under Linux and Windows. Mol. Ecol. Resour. 10(3), 564-567 (2010
57. Kleinbaum DG, Klein M. Logistic Regression: A Self Learning Text (2nd Edition). Springer, NY, USA (2002
58. Jaccard J. Interaction Effects in Logistic Regression (Quantitative Applications in the Social Sciences). SAGE publications, Inc., CA, USA (2001
59. Qadir M, O'Loughlin KL, Fricke SM et al. Cyclosporin A is a broad-spectrum multidrug resistance modulator. Clin. Cancer Res. 11(6), 2320-2326 (2005
60. Gupta A, Dai Y, Vethanayagam RR et al. Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan. Cancer Chemother. Pharmacol. 58(3), 374-383 (2006
61. Minocha M, Khurana V, Qin B, Pal D, Mitra AK. Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors. Int. J. Pharm. 434(1-2), 306-314 (2012
62. Kumar V, Brundage RC, Oetting WS, Leppik IE, Tracy TS. Differential genotype dependent inhibition of CYP2C9 in humans. Drug Metab. Dispos. 36(7), 1242-1248 (2008
63. Elens L, Hesselink DA, van Schaik RH, van Gelder T. The CYP3A4*22 allele affects the predictive value of a pharmacogenetic algorithm predicting tacrolimus predose concentrations. Br. J. Clin. Pharmacol. 75(6), 1545-1547 (2013
64. Vafadari R, Bouamar R, Hesselink DA et al. Genetic polymorphisms in ABCB1 influence the pharmacodynamics of tacrolimus. Ther. Drug Monit. 35(4), 459-465 (2013